Congo

• The Democratic Republic of the Congo is facing its deadliest Ebola outbreak in history, with the death toll now exceeding 2,300 people. • Official data reveals a total of 4,945 recorded cases and 2,325 deaths, marking a significant escalation in the disease's impact. • This surge is critical as it represents the highest mortality rate ever recorded for an Ebola outbreak within the Central African nation.

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 18, 2026, that it will soon begin a Phase II clinical trial for NV-387 oral gummies. • The trial aims to treat the Bundibugyo Ebola virus during what is described as the largest and most rapidly expanding outbreak to date in the Democratic Republic of Congo. • This development is critical as the company seeks to provide an accessible, antiviral treatment that prevents viral escape during a major public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo. • The trial aims to combat the current outbreak, which is described as the largest and most expanding in the region's history. • Led by Professor Katoto and supported by experts like Fogarty Fellow Patrick, the study leverages specialized implementation research networks to scale novel treatments.

At least 2,325 people have been killed, according to government data, surpassing the death toll from 2018-20 outbreakThe Ebola outbreak in the Democratic Republic of Congo is now the deadliest in the country’s history with at least 2,325 people killed, according to government data, surpassing the toll from the 2018-20 outbreak.Congo’s public health institute said on Sunday that confirmed cases had risen to 4,945, including 101 new cases detected in the previous 24 hours. Continue reading...

• NanoViricides, Inc. (NYSE American: NNVC) received regulatory approval on August 10, 2026, to launch a Phase II clinical trial for its NV-387 oral gummies. • The trial will take place in the Democratic Republic of Congo to treat patients affected by the current largest and most rapidly expanding Ebola outbreak. • This development is critical as the company aims to provide an accessible, antiviral treatment designed to prevent viral escape during a public health crisis.

• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies, designed as a treatment for the Ebola virus. • The trial will take place in the Democratic Republic of Congo to combat the largest and most rapidly expanding Ebola outbreak on record. • The urgency for the treatment is heightened by the virus spreading into displacement camps housing over 4.4 million people, where poor sanitation and medical resources increase risk.

• Health Canada has authorized Moderna to begin a clinical trial for an mRNA vaccine targeting the Bundibugyo strain of the Ebola virus. • The trial aims to combat a significant and ongoing outbreak of the virus currently surging throughout the Democratic Republic of the Congo. • This authorization is critical as it leverages mRNA technology to provide a rapid response to a deadly pathogen in a region facing a public health crisis.

• UN partners have launched the Winter Response Plan to provide critical aid to 2.1 million people in Ukraine to help them survive the upcoming cold season amid the ongoing Russian invasion. • In the Democratic Republic of Congo, at least 30 people were killed and dozens injured during attacks in the Beni territory between July 13 and 19. • The violence in DR Congo has forced at least six humanitarian organizations to suspend their operations and movements within the affected territory.

• UN human rights experts condemned the M23 armed group on Tuesday for orchestrating a "reign of terror" in eastern Democratic Republic of the Congo. • The Rwanda-backed group is accused of systemic sexual torture and violence targeting civilians within the territories it controls. • UNICEF has joined the call for an immediate end to these attacks, emphasizing the urgent need to protect children and humanitarian facilities.

• New clinical trials have been launched in the Democratic Republic of Congo to evaluate the efficacy of two drugs, MBP-134 and remdesivir, against the Bundibugyo Ebola virus. • These trials are critical because the Bundibugyo species currently lacks any approved vaccines or therapies to mitigate its spread. • The outbreak has already resulted in over 1,561 confirmed cases and more than 500 deaths, according to the CDC.